Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423327 · ClinicalTrials.gov registry record · NA
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
A NA study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- NA
- Development phase
- 5,311
- Enrollment target
NCT05423327 is a NA study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 5,311 participants.
The verdict
NCT05423327, a NA study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- NA
- Development phase
- 5,311 participants
- Enrollment target
Study Summary
Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
Interventions
- PROCEDURE No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,311 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2022-10-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05423327
The ClinicalTrials.gov registry entry for NCT05423327 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5,311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT05423327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05423327 about?
NCT05423327 is a clinical study titled "Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)". Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
What is the current status of trial NCT05423327?
This trial is currently terminated. It is a NA study. The enrollment target is 5,311 participants. The study started on 2021-12-09. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT05423327?
The interventions under investigation include: No Intervention (PROCEDURE).
Who is sponsoring clinical trial NCT05423327?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.